MA37425B1 - Bispecific anti-baff-anti-il-17 antibodies - Google Patents

Bispecific anti-baff-anti-il-17 antibodies

Info

Publication number
MA37425B1
MA37425B1 MA37425A MA37425A MA37425B1 MA 37425 B1 MA37425 B1 MA 37425B1 MA 37425 A MA37425 A MA 37425A MA 37425 A MA37425 A MA 37425A MA 37425 B1 MA37425 B1 MA 37425B1
Authority
MA
Morocco
Prior art keywords
baff
antibodies
bispecific antibodies
bispecific
ssp
Prior art date
Application number
MA37425A
Other languages
French (fr)
Other versions
MA37425A1 (en
Inventor
Barrett Allan
Robert Jan Benschop
Jirong Lu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority claimed from PCT/US2013/036677 external-priority patent/WO2013158577A1/en
Publication of MA37425A1 publication Critical patent/MA37425A1/en
Publication of MA37425B1 publication Critical patent/MA37425B1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des anticorps bispécifiques qui lient de manière spécifique le facteur d'activation des lymphocytes b de la famille du tnf (baff) et l'interleukine-17a (il-17) et sont caractérisés en qu'ils présentent une haute affinité et de fortes propriétés de neutralisation envers à la fois baff et il-17. Les anticorps bispécifiques de l'invention sont censés être utiles dans le traitement de la néphropathie lupique (nl), le lupus érythémateux disséminé (led), l'arthrite rhumatoïde (ar), le psoriasis (ps), la spondylarthrite ankylosante (sa), le rhumatisme psoriasique (rp), le syndrome de sjögren primaire (ssp) ou le myélome multiple (mm).The present invention relates to bispecific antibodies that specifically bind the activation factor of tnf (baff) family b-lymphocytes and interleukin-17a (il-17) and are characterized by having high affinity and strong neutralizing properties towards both baff and il-17. The bispecific antibodies of the invention are believed to be useful in the treatment of lupus nephropathy (nl), systemic lupus erythematosus (led), rheumatoid arthritis (ar), psoriasis (ps), ankylosing spondylitis (AS) , psoriatic arthritis (rp), primary sjögren's syndrome (ssp) or multiple myeloma (mm).

MA37425A 2012-04-20 2013-04-16 Bispecific anti-baff-anti-il-17 antibodies MA37425B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636302P 2012-04-20 2012-04-20
PCT/US2013/036677 WO2013158577A1 (en) 2012-04-20 2013-04-16 Anti-baff-anti-il-17 bispecific antibodies

Publications (2)

Publication Number Publication Date
MA37425A1 MA37425A1 (en) 2017-10-31
MA37425B1 true MA37425B1 (en) 2018-12-31

Family

ID=58044249

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37425A MA37425B1 (en) 2012-04-20 2013-04-16 Bispecific anti-baff-anti-il-17 antibodies

Country Status (2)

Country Link
MA (1) MA37425B1 (en)
UA (1) UA113080C2 (en)

Also Published As

Publication number Publication date
MA37425A1 (en) 2017-10-31
UA113080C2 (en) 2016-12-12

Similar Documents

Publication Publication Date Title
PH12014502333A1 (en) Anti-baff-anti-il-17 bispecific antibodies
PH12015501994A1 (en) Antibodies that bind il-23
EA201591478A1 (en) BISPECIFIC ANTIBODIES AGAINST TNF and IL-17
CU24597B1 (en) HETERODIMERIC BIESPECIFIC ANTIBODIES THAT BIND CD3 AND CD20
EA201300418A1 (en) ANTIBODIES TO THE HUMAN TWEAK AND VARIANTS OF THEIR APPLICATION
WO2013011076A3 (en) Tnf -alpha antigen- binding proteins with increased fcrn binding
WO2014114651A9 (en) Tnf-alpha antigen-binding proteins
MX365690B (en) Anti-hla-b*27 antibodies and uses thereof.
EA201892790A1 (en) APPLICATION OF 2-SUBSTITUTED INDAZOLS FOR THE TREATMENT AND PREVENTION OF AUTOIMMUNE DISEASES
MA35740B1 (en) Compositions and methods for antibodies targeting the factor p
MX2015007034A (en) Anti-blood dendritic cell antigen 2 antibodies and uses thereof.
EA201290360A1 (en) HUMANIZED ANTIBODIES AGAINST HUMAN IL-22RA
MA37946A1 (en) Treatment of rheumatoid arthritis
WO2009000929A3 (en) Composition and method for treatment of autoimmune disease
RU2016129167A (en) SPECIFIC ANTIBODIES TO ALPHA-ENOLASE AND METHOD OF APPLICATION FOR IMMUNE DISEASES
MA43088B1 (en) Anti-il-17c antibodies
MA37425A1 (en) Bispecific anti-baff-anti-il-17 antibodies
TN2014000413A1 (en) Anti-baff-anti-il-17 bispecific antibodies
EA201890741A1 (en) BISPECIFIC ANTIBODIES AGAINST CGRP / IL-23 AND THEIR APPLICATIONS
TH1401006266A (en) ANTI-BAFF-ANTI-IL-17 Bspecific Antibody
MA39559A1 (en) Glucocorticoid Induced Tumor Necrosis Factor Receptor Antibody (gitr) and their Uses
MA35686B1 (en) Anti-ox40 Antibodies and Methods of Use
UA99527C2 (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
UY30505A1 (en) PHENYLINDOLS AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEPTOR